Back

Eli Lilly and Company

Ticker: LLY ISIN: US5324571083
Add to portfolio Portfolio analysis in 2min
Stock Large-cap Dividend payer Trading above 200-day average
Market cap
$1.00T
P/E
37.75
Forward P/E
23.81
Profit margin
33.53%
Revenue growth QoQ
47.70%
Div. yield
0.57%
Beta
0.50
$1,124.21 0.03%
Price as of 2026-09-09 · NYSE

Performance by timeframe

Rolling returns
1 Month -7.34%
6 Months +15.40%
1 Year +49.92%
5 Years +37.69% p.a.+394.30%
10 Years +32.48% p.a.+1,562.11%
Since inception +14.36% p.a.+2,755.18%
Calendar year returns
YTD +5.11%
2025 +40.25%
2024 +33.30%
2023 +60.91%
2022 +34.24%
2021 +66.07%

Key stats

Market cap
1.00T
P/E
37.75
Dividend yield
0.57%
Beta
0.50
52-week range
707.59 - 1,292.65
50-day MA
1,187.70
200-day MA
1,064.17
Section 1

Business overview

Company profile data from fundamentals.

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Sector Healthcare
Industry Drug Manufacturers - General
Country United States
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 1.02%
ROA 20.36%
Profit margin 33.53%
Operating margin 54.22%
PEG ratio 1.09
Revenue/share TTM 89.02
Revenue TTM 79.67B
EBITDA 41.71B
Gross profit TTM 66.44B
Beta 0.50

Valuation

Trailing P/E 37.75
Forward P/E 23.81
P/B 29.57
P/S 12.58
EV/EBITDA 25.12
EV/Revenue 13.15
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 36.71
Quarterly earnings growth 26.20%
Revenue TTM 79.67B
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 0.57%
Dividend per share 6.4600
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Ownership & short interest

Short ratio 2.46
Short % of float 0.74%

Details

Instrument metadata and source update timestamps.

Symbol LLY
Name Eli Lilly and Company
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US5324571083
Country USA
Code + exchange LLY.NYSE
Last price date 2026-09-09
Fundamentals updated 2026-09-10

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.